For Q1 FY2026 ended March 31, 2026, Myriad Genetics reported revenue of $200.4 million, up 2.3% year-over-year. Net loss was $34.1 million, compared to a net loss of $0.1 million in the prior year quarter. Operating loss was $30.7 million, widening 5.9% from a year ago. Diluted EPS was -$0.36.
•Revenue grew 2.3% YoY to $200.4 million.
•Net loss widened to $34.1 million from $0.1 million.
•Operating loss increased 5.9% to $30.7 million.
•Cash and cash equivalents stood at $124.4 million with long-term debt of $120.3 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics, as well as MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers.
Its portfolio also includes BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants, and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. Additionally, it offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer.
Its portfolio also includes EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer, Precise Tumor Molecular Profile test, a genomic profiling test, Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus, Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring, SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus, FirstGene, and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and mental health conditions.
It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center. Its portfolio also includes Mayo Foundation for Medical Education and Research, Children's Medical Center in Boston, Institut Curie and INSERM, and Eurobio Scientific SA. Founded in 1991, the company is headquartered in Salt Lake City, Utah.
Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops and markets molecular tests. Its primary focus is on oncology, women's health, and pharmacogenomics. Key products include the MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx, a companion diagnostic for certain cancers; MyChoice CDx for ovarian cancer; Prolaris for prostate cancer aggressiveness; EndoPredict for breast cancer prognosis; and Precise Tumor Molecular Profile for genomic profiling. In women's health, it offers Prequel Prenatal Screen, Foresight Carrier Screen, and SneakPeek Early Gender DNA test. For mental health, the GeneSight Psychotropic test aids drug selection. The company operates in the United States and is listed on the NasdaqGS under the ticker MYGN.
Where is Myriad Genetics (MYGN) listed and what currency does it trade in?
Myriad Genetics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol MYGN. Its securities are traded in US Dollars (USD), reflecting its primary listing in the United States. The company is headquartered in the United States and its stock is part of the US equity market, making it accessible to investors through US-based brokerages. The NasdaqGS is a major US exchange known for listing many technology and healthcare companies, and Myriad Genetics' presence there underscores its position in the molecular diagnostics and precision medicine sector.
What sector and industry does Myriad Genetics (MYGN) belong to?
Myriad Genetics operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This industry encompasses companies that provide diagnostic testing services, laboratory analysis, and research tools for medical applications. As a molecular diagnostics and precision medicine company, Myriad Genetics develops tests that help identify genetic predispositions, guide treatment decisions, and assess disease prognosis. Its focus on oncology, women's health, and pharmacogenomics aligns with the broader healthcare trend toward personalized medicine. The Diagnostics & Research industry is critical for advancing early detection and targeted therapies, and Myriad Genetics is a key player in this space with a portfolio of FDA-approved and laboratory-developed tests.
What are the main products and services offered by Myriad Genetics (MYGN)?
Myriad Genetics offers a comprehensive suite of molecular diagnostic tests across several medical areas. In oncology, its products include MyRisk Hereditary Cancer test for hereditary cancer risk, BRACAnalysis CDx for germline BRCA variants in certain cancers, MyChoice CDx for homologous recombination deficiency in ovarian cancer, Prolaris for prostate cancer aggressiveness, EndoPredict for breast cancer prognosis, and Precise Tumor Molecular Profile for comprehensive genomic profiling. In women's health, it provides Prequel Prenatal Screen for chromosomal disorders, Foresight Carrier Screen for recessive genetic conditions, and SneakPeek Early Gender DNA test. For mental health, the GeneSight Psychotropic test helps guide medication selection for depression and anxiety. These tests are used by healthcare providers to inform diagnosis, treatment, and risk assessment.
What is the business model of Myriad Genetics (MYGN) and how does it generate revenue?
Myriad Genetics generates revenue primarily by selling its molecular diagnostic tests to healthcare providers, hospitals, laboratories, and patients. The company operates as a commercial-stage diagnostics firm, deriving income from test reimbursements by insurance companies, Medicare, and other payers, as well as direct payments from patients. Its tests are developed in-house and marketed through a direct sales force and partnerships. The company's focus on precision medicine means it often works with oncologists, genetic counselors, and women's health specialists to integrate its tests into clinical practice. By offering a broad portfolio covering hereditary cancer, prenatal screening, pharmacogenomics, and tumor profiling, Myriad Genetics captures value across multiple diagnostic segments. Revenue is also supported by companion diagnostic collaborations with pharmaceutical companies for drug development.